WVE:NASDAQWave Life Sciences Ltd. Analysis
Data as of 2026-08-31 - not real-time
$5.04
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Wave Life Sciences, Inc. trades at $5.04, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. The last 30 days have lost 13.4%. Relative strength is 39.0 — approaching oversold — and the MACD signal is bearish. Price has been bracketed by support at $5.01 and resistance at $6.41.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 278.2% above the current price. Revenue is contracting at 73.9%.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 67.7%, a beta of 1.32 and a maximum drawdown of 76.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 2 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 278.2% above the current price. Revenue is contracting at 73.9%.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 67.7%, a beta of 1.32 and a maximum drawdown of 76.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 2 out of 10.
Top Market Events
Wave Life Sciences Ltd. reported second-quarter 2026 results with sales of US$2.27 million versus US$8.70 million a...CAMBRIDGE, Mass., Aug. 05, 2026 GLOBE NEWSWIRE -- As previously announced, Wave Life Sciences Ltd. NASDAQ: WVE , a...CAMBRIDGE, Mass., Aug. 05, 2026 GLOBE NEWSWIRE -- As previously announced, Wave Life Sciences Ltd. NASDAQ: WVE , a...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 9.36
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 9.36
- Analyst targets imply +278.2% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Analyst targets imply +278.2% versus the current price
- Negative return on equity of -67.4%
- Revenue contracting at -73.9%
Key Metrics & Analysis
Financial Health
Revenue Growth-73.90%
P/E Ratio-4.2
ROE-67.42%
ROA-33.60%
Debt/Equity9.61
P/B Ratio1.8
Op. Cash Flow$-191576992
Free Cash Flow$-128778376
Industry P/E30.3
Technical Analysis
TrendBearish
RSI39.0
Support$5.01
Resistance$6.41
MA 20$5.44
MA 50$5.74
MA 200$9.36
MACDBearish
VolumeDecreasing
Fear & Greed Index94.11
Valuation
Target Price$19.06
Upside/Downside278.22%
GradeFair
TypeBlend
Risk Assessment
Beta1.32
Volatility67.71%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.